Celularity (CELU) AI Stock Analysis

• Market Cap: $86.46M
• Dividend Yield: N/A
• Average Volume (3M): 414.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.56
• Revenue Growth: 138.11%
• EPS Growth: 76.60%
• Country: US
• Employees: 120
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 23,949,228
• 10 Day Avg. Volume: 67,740
• 30 Day Avg. Volume: 414,994
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.75
• Price Target Upside: 31.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 56 Neutral
• Price Target: $3.50 ▼(-3.05% Downside)

Celularity's stock score is primarily influenced by its strong technical momentum and positive corporate restructuring, which reduced debt. However, financial performance and valuation remain weak due to ongoing losses and high leverage.

Celularity Business Overview & Revenue Model

Company Description

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

How the Company Makes Money

Celularity makes money through the development and commercialization of its proprietary allogeneic cellular therapies. The company's revenue model is primarily driven by the sale of its therapeutic products, which are developed through its placenta-derived cellular platform. Key revenue streams include partnerships with pharmaceutical companies, collaborations, and potential licensing agreements where Celularity provides access to its technology and products. The company may also receive funding from grants and institutional investors to support its research and development activities. Significant factors contributing to its earnings include advancements in its clinical trials, regulatory approvals, and the successful commercialization of its therapies.

Celularity Financial Statement Overview

Summary

Celularity shows strong revenue growth but remains unprofitable with high operational expenses. The balance sheet indicates high leverage and declining equity, raising financial stability concerns. Cash flows are negative but improving, supported by financing activities.

Income Statement

Celularity has shown a significant increase in revenue, growing from $22.8 million in 2023 to $54.2 million in 2024. However, the company remains unprofitable with a negative net profit margin due to high operational expenses, as indicated by negative EBIT and EBITDA margins. The gross profit margin improved to 83.6% in 2024 from 29.7% in 2023, which is a positive sign of operational efficiency.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio of 3.29 in 2024, indicating financial risk. The equity ratio is low at 6.7%, showing limited equity buffer. The stockholders' equity has decreased significantly, reflecting potential financial instability and risk.

Cash Flow

Celularity's free cash flow remains negative, but has improved from -$42.7 million in 2023 to -$6.56 million in 2024. The operating cash flow to net income ratio is negative, highlighting ongoing cash drain. However, the company successfully raised funds through financing activities, providing some liquidity cushion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.22M	22.77M	17.98M	21.34M	14.28M
Gross Profit	45.33M	6.75M	-1.69M	11.68M	9.35M
EBITDA	-43.71M	-183.95M	23.58M	-88.11M	-202.41M
Net Income	-57.89M	-196.29M	14.19M	-100.12M	-208.23M
Balance Sheet
Total Assets	132.68M	143.89M	401.07M	414.13M	431.01M
Cash, Cash Equivalents and Short-Term Investments	738.00K	227.00K	13.97M	37.24M	54.31M
Total Debt	29.03M	65.42M	65.59M	31.14M	30.64M
Total Liabilities	123.84M	102.93M	202.16M	314.71M	962.41M
Stockholders Equity	8.84M	40.96M	198.90M	99.42M	-531.40M
Cash Flow
Free Cash Flow	-6.56M	-42.73M	-143.11M	-116.30M	-91.03M
Operating Cash Flow	-6.40M	-38.69M	-137.88M	-110.10M	-63.19M
Investing Cash Flow	514.00K	-4.05M	-5.24M	-5.90M	-12.81M
Financing Cash Flow	6.70M	24.09M	119.84M	98.56M	102.01M

Celularity Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Positive. The current price of 3.61 is above the 20-day moving average (MA) of 3.35, above the 50-day MA of 2.66, and above the 200-day MA of 2.17, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 58.21 is Neutral, neither overbought nor oversold. The STOCH value of 46.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CELU.

Celularity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	60 Neutral	$65.73M	―	-69.96%	―	-99.64%	-59.17%
CELU	56 Neutral	$86.46M	―	-232.51%	―	138.11%	76.60%
Sector *	51 Neutral	$7.77B	-0.12	-39.78%	2.21%	22.68%	-1.42%
GBIO	50 Neutral	$43.04M	―	-85.45%	―	61.15%	54.71%
STTK	47 Neutral	$49.34M	―	-73.39%	―	-27.33%	34.66%
LTRN	45 Neutral	$48.17M	―	-88.59%	―	―	-8.47%
FBLG	38 Underperform	$24.67M	―	-559.73%	―	―	43.68%

Celularity Corporate Events

Celularity Sells IP to Celeniv, Reduces Debt

On August 13, 2025, Celularity Inc. entered into an asset purchase agreement with Celeniv Pte. Ltd., selling certain intellectual property for $33,812,230, which was used to retire all senior secured debt. The agreement included a license back of the IP to Celularity with a five-year repurchase option. This restructuring eliminated $41.6 million in debt, improved financial flexibility, and led to the creation of four wholly-owned subsidiaries to enhance operational efficiency across its commercial units.

Celularity Enters Series Seed Stock Agreement with Defeye

Celularity Inc. entered into a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc. on August 5, 2025, involving the issuance of 7,198.630 shares of Series Seed-2 Preferred Stock in exchange for $2,890,250 of product purchase credits. Additionally, Celularity faced compliance issues with Nasdaq due to a delay in filing its quarterly report for the quarter ended March 31, 2025. The company submitted a compliance plan on August 1, 2025, and was given until August 31, 2025, to file the necessary reports to avoid delisting.

Celularity Issues Promissory Note and Warrant

On July 21, 2025, Celularity Inc. issued a promissory note worth $6,812,230 to an investor, along with a warrant to purchase 3,700,000 shares of Class A common stock at $2.528 per share, exercisable for five years. The note, bearing a 2% annual interest rate and maturing on March 21, 2026, is secured by the company’s assets and will be partially used to settle a loan from C.V. Starr & Co. This financial maneuver is expected to impact Celularity’s operations by addressing existing debt obligations and potentially influencing its market positioning.

Celularity Secures $2M Through Private Placement Deal

On July 14, 2025, Celularity Inc. entered into a securities purchase agreement with an institutional investor for a private placement of 1,230,769 shares of Class A common stock and warrants, expecting gross proceeds of $2,000,000. The company plans to use the net proceeds for working capital and general corporate purposes, potentially impacting its operational capacity and market positioning.

Celularity Finalizes Private Placement Agreement

On June 23, 2025, Celularity Inc. entered into a securities purchase agreement with certain investors for a private placement of 739,286 shares of Class A common stock at $1.40 per share. The agreement also included a warrant adjustment for 1,311,093 warrants, revising the exercise price to $2.50 per share and extending the expiration date to June 30, 2030. The closing is expected during the week of July 21, 2025, with gross proceeds anticipated at $1,035,000, intended for working capital and general corporate purposes.

Celularity Extends Note Maturity with YA II PN

On May 20, 2025, Celularity Inc. entered into a letter agreement with YA II PN, Ltd. to extend the maturity date of a Convertible Promissory Note from May 12, 2025, to August 15, 2025. In exchange, Celularity issued 100,000 shares of restricted common stock to YA, which will have piggyback registration rights for resale in future registration statements filed by the company.